Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEMI-first: Cemiplimab as first-line treatment for advanced basal cell carcinoma
2024-517647-31-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in basal cell carcinoma (BCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: ORR at 6 months. Planned start Feb 2025; status: authorised.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2024-517647-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517647-31-00.